Catalent (CTLT) Financial Analysis & Valuation | Quarter Chart
Catalent (CTLT)
CTLTPrice: $63.48
Fair Value: 🔒
🔒score
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clini... more
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, prote... more
Description
Shares
| Market Cap | $11.52B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | US | CEO | Alessandro Maselli |
| IPO Date | 2014-07-31 | CAGR | 0.08% |
| Employees | 17,000 | Website | www.catalent.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CTLT chart loading...
Fundamentals
Technicals
| Enterprise Value | $15.64B | P/E Ratio | -27.84 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 3.39 | P/B Ratio | 3.26 |
| P/CF Ratio | 40.26 | P/FCF Ratio | 142.25 |
| EPS | $-2.28 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 4.39% | Gross Margin | 0.23% |
| Operating Margin | 0.02% | Profit Margin | -0.06% |
| ROE | -0.06% | ROA | -0.02% |
| ROCE | 0.01% | Current Ratio | 2.51 |
| Quick Ratio | 1.96 | Cash Ratio | 0.34 |
| Debt/Equity | 1.4 | Interest Coverage | 0.38 |
| Altman Z Score | 1.62 | Piotroski Score | 4 |